Experience by Indication
SOLID
• Anaplastic Astrocytoma
• Breast Cancer
• Renal Cell Carcinoma
• Basal Cell Carcinoma
• Melanoma
• Gastrointestinal Stromal Tumor
• Ovarian Cancer
• Prostate Cancer
• Colorectal Cancer
• Small Cell Lung Cancer
• Hormone-Refractory Prostate Cancer
• Non-Small Cell Lung Cancer
• Gastric Cancer
• Head & Neck
• Glioblastoma
• Bladder Cancer
• Cervical Carcinoma
• Fallopian Tube Cancer
• Phase I Solid Tumors
• Liver Cancer
• Pancreatic Cancer
• Pediatric Solid Tumors
• Peritoneal Cancer
• Rare Cancer Types
• Urothelial Cancer
HEMATOLOGIC
• Chronic Lymphocytic Leukemia
• Chronic Myelogenous Leukemia
• Chronic Myelomonocytic Leukemia
• Non Hodgkin’s Lymphoma
– Indolent B-Cell Lymphomas
– Follicular lymphoma (FL)
– Diffuse Large B-Cell lymphoma
– Small lymphocytic lymphoma (SLL)
– Marginal zone lymphoma
– Lymphoplasmacytic lymphoma
• Acute Myeloid Leukaemia
• Primary Central Nervous System Lymphoma (PCNSL)
• Multiple Myeloma
• Myelodysplastic syndromes (MDS)
• Phase I Various Hematological Malignancies
• Peripheral T-cell Lymphoma
• Cutaneous T-cell Lymphoma
Experience by Drug Modalities
• Cytotoxics
• Antiangiogenic small molecules
• Antigen Presenting Cell (APC)
• Anti-metabolite
• Antibody Drug Conjugates (ADC)
• Biomarker
• Chemotherapy
• Gene therapies
• Glutaminase inhibitors
• Hormones
• Hedgehog pathway inhibitors
• Immunotherapeutic product obtained from leukapheresis
• Monoclonal antibodies (mAb)
• Oncologic vaccine
• Oligonucleotide
• Opioid
• Peptides
• Photosensitizing agent
• Radiopharmaceuticals
• Radioactive imaging agent
• Recombinant DNA
(single-strand DNA)
• Retroviral replicating vector
• Small molecules
• (Stem) cell therapies
• Vaccines
Clinical Team Experience
• Basket trials
• Rare diseases
• Radionuclide therapeutics products
• Inspections by regulatory agencies’
• Pediatric population
• Radiopharmacies
• Registrational trials